These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 23452867)

  • 1. The OxyContin crisis: problematisation and responsibilisation strategies in addiction, pain, and general medicine journals.
    Whelan E; Asbridge M
    Int J Drug Policy; 2013 Sep; 24(5):402-11. PubMed ID: 23452867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Representations of OxyContin in North American newspapers and medical journals.
    Whelan E; Asbridge M; Haydt S
    Pain Res Manag; 2011; 16(4):252-8. PubMed ID: 22059195
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trends in abuse of Oxycontin and other opioid analgesics in the United States: 2002-2004.
    Cicero TJ; Inciardi JA; Muñoz A
    J Pain; 2005 Oct; 6(10):662-72. PubMed ID: 16202959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prescription Opioid Misuse Index: a brief questionnaire to assess misuse.
    Knisely JS; Wunsch MJ; Cropsey KL; Campbell ED
    J Subst Abuse Treat; 2008 Dec; 35(4):380-6. PubMed ID: 18657935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. OxyContin in Ontario: the multiple materialities of prescription painkillers.
    King S
    Int J Drug Policy; 2014 May; 25(3):486-93. PubMed ID: 24612641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. OxyContin abuse and overdose.
    Aquina CT; Marques-Baptista A; Bridgeman P; Merlin MA
    Postgrad Med; 2009 Mar; 121(2):163-7. PubMed ID: 19332974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A profile of OxyContin addiction.
    Hays LR
    J Addict Dis; 2004; 23(4):1-9. PubMed ID: 15339710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Seeking drug treatment for OxyContin abuse: a chart review of consecutive admissions to a substance abuse treatment facility in Kentucky.
    Hays L; Kirsh KL; Passik SD
    J Natl Compr Canc Netw; 2003 Jul; 1(3):423-8. PubMed ID: 19761073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The development of a comprehensive risk-management program for prescription opioid analgesics: researched abuse, diversion and addiction-related surveillance (RADARS).
    Cicero TJ; Dart RC; Inciardi JA; Woody GE; Schnoll S; Muñoz A
    Pain Med; 2007 Mar; 8(2):157-70. PubMed ID: 17305687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High dose controlled-release oxycodone in hospice care.
    Bercovitch M; Adunsky A
    J Pain Palliat Care Pharmacother; 2006; 20(4):33-9. PubMed ID: 17182504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prescription OxyContin abuse among patients entering addiction treatment.
    Carise D; Dugosh KL; McLellan AT; Camilleri A; Woody GE; Lynch KG
    Am J Psychiatry; 2007 Nov; 164(11):1750-6. PubMed ID: 17974941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. OxyContin use and misuse in three populations: substance abuse patients, pain patients, and criminal justice participants.
    Wunsch MJ; Cropsey KL; Campbell ED; Knisely JS
    J Opioid Manag; 2008; 4(2):73-9. PubMed ID: 18557163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 'Not an appropriate use'. Did the makers of OxyContin push too hard?
    Spake A
    US News World Rep; 2001 Jul; 131(1):26. PubMed ID: 11447650
    [No Abstract]   [Full Text] [Related]  

  • 14. OxyContin: maintaining availability and efficacy while preventing diversion and abuse.
    Regan JJ; Alderson A
    Tenn Med; 2003 Feb; 96(2):88-90. PubMed ID: 12645369
    [No Abstract]   [Full Text] [Related]  

  • 15. Addressing OxyContin abuse.
    FDA Consum; 2001; 35(4):3. PubMed ID: 11692884
    [No Abstract]   [Full Text] [Related]  

  • 16. The 'poor man's heroin'. An Ohio surgeon helps feed a growing addiction to OxyContin.
    Cohen G
    US News World Rep; 2001 Feb; 130(6):27. PubMed ID: 11216230
    [No Abstract]   [Full Text] [Related]  

  • 17. The marketing of OxyContin®: A cautionary tale.
    Egilman DS; Collins GDYCB; Falender J; Shembo N; Keegan C; Tohan S
    Indian J Med Ethics; 2019; 4(3):183-193. PubMed ID: 31727614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The danger of imperfect regulation: OxyContin use in the United States and Canada.
    Lexchin J; Kohler JC
    Int J Risk Saf Med; 2011; 23(4):233-40. PubMed ID: 22156088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. On what basis did Health Canada approve OxyContin in 1996? A retrospective analysis of regulatory data.
    Pappin J; Bavli I; Herder M
    Clin Trials; 2022 Oct; 19(5):584-590. PubMed ID: 35924783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Attractiveness of reformulated OxyContin(R) tablets: assessing comparative preferences and tampering potential.
    Sellers EM; Perrino PJ; Colucci SV; Harris SC
    J Psychopharmacol; 2013 Sep; 27(9):808-16. PubMed ID: 23784739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.